×
Amarin Receivables 2010-2025 | AMRN
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Amarin receivables from 2010 to 2025. Receivables can be defined as the total amount of collectibles for a company
View More
Amarin Receivables 2010-2025 | AMRN
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Amarin receivables from 2010 to 2025. Receivables can be defined as the total amount of collectibles for a company
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$249.5B
Amgen (AMGN)
$159.2B
Gilead Sciences (GILD)
$144.1B
Vertex Pharmaceuticals (VRTX)
$101.9B
Bristol Myers Squibb (BMY)
$98.6B
GSK (GSK)
$81.7B
CSL (CSLLY)
$69.9B
Regeneron Pharmaceuticals (REGN)
$63.4B
Alnylam Pharmaceuticals (ALNY)
$61.3B
Argenex SE (ARGX)
$40.6B
Insmed (INSM)
$28B
BioNTech SE (BNTX)
$26.6B
Royalty Pharma (RPRX)
$21.2B
Biogen (BIIB)
$20.4B
Incyte (INCY)
$16.9B
Genmab (GNMSF)
$16.1B
Genmab (GMAB)
$15.7B
Illumina (ILMN)
$15.3B
Ascendis Pharma (ASND)
$11.8B
BioMarin Pharmaceutical (BMRN)
$11.2B
QIAGEN (QGEN)
$10.9B
Exelixis (EXEL)
$10.4B
Swedish Orphan Biovitrum (BIOVF)
$10.3B
Moderna (MRNA)
$10.2B
Verona Pharma American Depositary Share (VRNA)
$9B
Exact Sciences (EXAS)
$8.8B
Bio-Techne Corp (TECH)
$8.5B
Halozyme Therapeutics (HALO)
$8.4B
Blueprint Medicines (BPMC)
$8.3B
Roivant Sciences (ROIV)
$8B